Entos Pharmaceuticals


Developer of nucleic acid therapeutics delivery technologies based on a fusion protein-mediated viral–lipid hybrid platform. Activities described on the site include platform R&D, plasmid DNA vaccine development (early-phase clinical evaluation), formulation and scale-up work, GMP manufacturing operations, preclinical in vivo research, assay development, and partnership activity.

Industries

Biotechnology
Health Care
Pharmaceutical
Biotechnology Research

Nr. of Employees

medium (51-250)

Entos Pharmaceuticals


Patents

Recombinant polypeptides for membrane fusion and uses thereof

US-12454557-B2

View Details

Methods for diagnosing and treating metastatic cancer

US-12421514-B2

View Details

Recombinant oncolytic viruses for treatment of metastatic cancers

US-12378289-B2

View Details

Recombinant polypepties for membrane fusion and uses thereof

US-11459362-B2

View Details

Methods for diagnosing and treating metastatic cancer

US-11236331-B2

View Details

Recombinant polypeptides for membrane fusion and uses thereof

US-10227386-B2

View Details

Products

Fusion protein-mediated viral–lipid hybrid delivery platform (nucleic acid delivery)

A delivery platform that uses fusion proteins and viral–lipid hybrid particles to enable direct membrane fusion delivery of nucleic acid payloads with the goal of achieving targeted biodistribution and redosable dosing.

Plasmid DNA COVID-19 booster vaccine candidate (fridge-stable pDNA formulation)

A plasmid DNA vaccine booster candidate formulated for refrigerated stability that is being evaluated in an early-phase clinical trial; described advantages include strong T-cell responses and lower cold-chain requirements compared with some existing vaccines.

ENTVAX002 - COVID-19 Booster Vaccine

ENTVAX002 is a COVID-19 booster vaccine that delivers a pDNA cargo in an optimized Fusogenix PLV vaccine formulation, currently being evaluated in a phase I/II clinical trial.

Fusogenix PLV

A revolutionary fusogenic lipid nanoparticle delivery platform formulated with proprietary FAST proteins to drive direct intracellular delivery of genetic medicine payloads.

ENTLEP001

A gene therapy that leverages the Fusogenix PLV systemic formulation and encodes the leptin hormone for the treatment of obesity and metabolic diseases.

ENTSTAR001

ENTSTAR001 is a gene therapy utilizing the Fusogenix PLV platform to deliver a functional full length copy of ABCA4 to the retina for the treatment of Stargardt disease.

View All Products

Expertise Areas

  • Genetic medicine delivery systems
  • Nucleic acid vaccine development (pDNA)
  • Biomanufacturing and CMC
  • Formulation development and stability
  • Show More (4)

Key Technologies

  • Plasmid DNA (pDNA) vaccines
  • Fusion protein-mediated viral–lipid hybrid delivery
  • Lipid nanoparticle formulations
  • AI-based biodistribution targeting
  • Show More (4)

News & Updates

Announcement of a partnership to accelerate biomanufacturing of next-generation therapeutics.

Reported partnership and funding with the governments of Canada and Alberta to support biomanufacturing of next-generation therapeutics.

Listed on the company's news pages as an award/recognition.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.